Active, not recruitingEarly Phase 1NCT07272525

Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease

Studying CACH syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Intervention: Fosigotifator (FGT/ABBV-CLS-7262)(drug)
Enrollment: 1 enrolled
Eligibility: All sexes
Timeline: 2024 – 2027

Study locations (1)

McGill University Health Centre, Montreal, Quebec, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07272525 on ClinicalTrials.gov

← Back to all trials